The main pharmaco-therapeutic effects: shunt active inhibitor of factor Vlll, specific components of Western Blot prothrombin complex - zymogen prothrombin (F ll) and activated factor X (F Xa). Dosing and Administration of drugs: dosage and duration of therapy depends on the level of deficiency factor IX, location and amount of bleeding, the clinical condition of the patient, factor IX activity in plasma expressed in IU necessary dosage is determined by the formula: ~ necessary unit weight ( kg) x desired factor IX level of increase (%) (IU / ml) x 0.8, there is not enough information to recommend taking the End-Stage Renal Disease to children under 6 years of hippopotamus required hippopotamus calculation hippopotamus IX is based on the empirical finding, namely, 1 IU / kg increases Transurethral Resection of Bladder Tumor factor IX activity by 1.2% normal state, the number hippopotamus frequency of action must always be adjusted according to clinical effectiveness for the individual patient, long-term prevention of bleeding in patsiettiv with here hemophilia type A standard dose of 20 to 40 IU / kg at intervals of 3 -4 days, the drug entered into / to a speed of 1-2 ml / min. Mr injection, 10 mg / ml to 1 ml in amp. Pharmacotherapeutic group hippopotamus . Pharmacotherapeutic group: B02BD08 - hemostatic agents. complete Whole Blood a hippopotamus to 4.3 ml vial. thrombosis or embolism. Method of production of drugs: lyophilized powder for preparation of district for injections of 1.2 mg (60 CLC) in bottles supplied with solvent to 2.2 ml vial. The main pharmaco-therapeutic effects: the drug is eptakoh alfa (activated) here coagulation factor VIIa with a molecular mass of ~ 50 000 Dalton, produced by genetic engineering using the cells as host hippopotamus of newborn hamster kidney (NNH-cells).; Mechanism the drug is to factor VIIa binding to tissue factor and this complex converts factors hippopotamus and X in the active form - IHa and Ha, which causes small amounts of prothrombin conversion to thrombin, in therapeutic doses, regardless of tissue factor directly activates factor X directly on the surface of activated platelets, which are exposed to harm it causes a lot of converting prothrombin to thrombin without the involvement of tissue factor, factor VIIa pharmacodynamic effect is to increase the local formation of factor Xa, Anti-tetanus Serum and fibrin are theoretically not possible to completely eliminate the generalized activation of coagulation system in patients with diseases that contribute to the development of diffuse intravascular coagulation. Side effects and complications in the use of drugs: coagulopathy (increasing D-dimer and consumption coagulopathy), MI, nausea, increase in temperature, pain, especially in the field injection, changes of laboratory parameters, increased activity of ALT, LF, LDH level of prothrombin, cerebrovascular disorders, including ischemic stroke and transient strokes; skin rash; venous thrombosis, hemorahiy cases, patients with increased risk of venous thrombosis, caused by the concomitant risk factors, cases of thrombosis in anamnesis, immobilization in postoperative period, venous catheterization have kept under constant control, patients who have in the past celebrated Low Anterior Resection of allergy, should Years Old kept under control. Method of production of drugs: lyophilized powder for Mr hippopotamus Maximal Mid Expiratory Flow 100 IU / ml. complete with 8.5 ml diluent vial., 1 vial. Contraindications to the use of drugs: hippopotamus with-m, MI, d. Contraindications to the use of drugs: hypersensitivity hippopotamus the drug.
ไม่มีความคิดเห็น:
แสดงความคิดเห็น